FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912132559> ?p ?o ?g. }

• W2912132559 endingPage "85" @default.
• W2912132559 startingPage "74" @default.
• W2912132559 abstract "Paediatric Strategy Forums have been created by the multistakeholder organisation, ACCELERATE, and the European Medicines Agency to facilitate dialogue between all relevant stakeholders and suggest strategies in critical areas of paediatric oncology drug development. As there are many medicines being developed for B-cell malignancies in adults but comparatively few in children with these malignancies, a Paediatric Strategy Forum was held to discuss the best approach to develop these products for children. It was concluded that as current frontline therapy is highly successful, despite associated acute toxicity, de-escalation of this or substitution of presently used drugs with new medicines can only be undertaken when there is an effective salvage regimen, which is currently not available. Therefore priority should be given to developing treatment for patients with relapsed and refractory mature B-cell lymphomas. The consensus of the clinicians attending the meeting was that CAR T-cells, T-cell engagers and antibody drug conjugates (excluding those with a vinca alkaloid-like drug) presently have the greatest probability of providing benefit in relapse in view of their mechanism of action. However, as producing autologous CAR T-cells currently takes at least 4 weeks, they are not products which could be quickly employed initially at relapse in rapidly progressing mature B-cell malignancies but only for the consolidation phase of the treatment. Global, industry-supported, academic-sponsored studies testing compounds from different pharmaceutical companies simultaneously should be considered in rare populations, and it was proposed that an international working group be formed to develop an overarching clinical trials strategy for these disease groups. Future Forums are planned for other relevant paediatric oncologic diseases with a high unmet medical need and relevant molecular targets." @default.
• W2912132559 created "2019-02-21" @default.
• W2912132559 creator A5001225108 @default.
• W2912132559 creator A5007455653 @default.
• W2912132559 creator A5008077943 @default.
• W2912132559 creator A5012101254 @default.
• W2912132559 creator A5018886099 @default.
• W2912132559 creator A5019914745 @default.
• W2912132559 creator A5020812442 @default.
• W2912132559 creator A5021322016 @default.
• W2912132559 creator A5021929662 @default.
• W2912132559 creator A5022107546 @default.
• W2912132559 creator A5022480009 @default.
• W2912132559 creator A5024202047 @default.
• W2912132559 creator A5024364773 @default.
• W2912132559 creator A5024908677 @default.
• W2912132559 creator A5027105415 @default.
• W2912132559 creator A5034043513 @default.
• W2912132559 creator A5039813382 @default.
• W2912132559 creator A5041362225 @default.
• W2912132559 creator A5042529049 @default.
• W2912132559 creator A5047353384 @default.
• W2912132559 creator A5048369262 @default.
• W2912132559 creator A5049106961 @default.
• W2912132559 creator A5049814181 @default.
• W2912132559 creator A5051298107 @default.
• W2912132559 creator A5051824759 @default.
• W2912132559 creator A5052706160 @default.
• W2912132559 creator A5055085063 @default.
• W2912132559 creator A5061470535 @default.
• W2912132559 creator A5065115707 @default.
• W2912132559 creator A5066484657 @default.
• W2912132559 creator A5067202962 @default.
• W2912132559 creator A5073848195 @default.
• W2912132559 creator A5076592063 @default.
• W2912132559 creator A5082440106 @default.
• W2912132559 creator A5085820190 @default.
• W2912132559 creator A5086736476 @default.
• W2912132559 creator A5087598270 @default.
• W2912132559 creator A5090929774 @default.
• W2912132559 creator A5091536705 @default.
• W2912132559 date "2019-03-01" @default.
• W2912132559 modified "2023-10-16" @default.
• W2912132559 title "ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children" @default.
• W2912132559 cites W1521582839 @default.
• W2912132559 cites W1598609271 @default.
• W2912132559 cites W1909351762 @default.
• W2912132559 cites W1964898740 @default.
• W2912132559 cites W1974184061 @default.
• W2912132559 cites W1997647834 @default.
• W2912132559 cites W2000871066 @default.
• W2912132559 cites W2005821972 @default.
• W2912132559 cites W2018071905 @default.
• W2912132559 cites W2031180703 @default.
• W2912132559 cites W2045940197 @default.
• W2912132559 cites W2056545314 @default.
• W2912132559 cites W2077362224 @default.
• W2912132559 cites W2078069330 @default.
• W2912132559 cites W2078494488 @default.
• W2912132559 cites W2156073127 @default.
• W2912132559 cites W2159263318 @default.
• W2912132559 cites W2171356556 @default.
• W2912132559 cites W2410714231 @default.
• W2912132559 cites W2417043811 @default.
• W2912132559 cites W2439114453 @default.
• W2912132559 cites W2642730068 @default.
• W2912132559 cites W2737907117 @default.
• W2912132559 cites W2742627598 @default.
• W2912132559 cites W2743064314 @default.
• W2912132559 cites W2754365127 @default.
• W2912132559 cites W2766047668 @default.
• W2912132559 cites W2795866094 @default.
• W2912132559 cites W2830196938 @default.
• W2912132559 cites W2878403994 @default.
• W2912132559 doi "https://doi.org/10.1016/j.ejca.2019.01.013" @default.
• W2912132559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30772656" @default.
• W2912132559 hasPublicationYear "2019" @default.
• W2912132559 type Work @default.
• W2912132559 sameAs 2912132559 @default.
• W2912132559 citedByCount "37" @default.
• W2912132559 countsByYear W29121325592019 @default.
• W2912132559 countsByYear W29121325592020 @default.
• W2912132559 countsByYear W29121325592021 @default.
• W2912132559 countsByYear W29121325592022 @default.
• W2912132559 countsByYear W29121325592023 @default.
• W2912132559 crossrefType "journal-article" @default.
• W2912132559 hasAuthorship W2912132559A5001225108 @default.
• W2912132559 hasAuthorship W2912132559A5007455653 @default.
• W2912132559 hasAuthorship W2912132559A5008077943 @default.
• W2912132559 hasAuthorship W2912132559A5012101254 @default.
• W2912132559 hasAuthorship W2912132559A5018886099 @default.
• W2912132559 hasAuthorship W2912132559A5019914745 @default.
• W2912132559 hasAuthorship W2912132559A5020812442 @default.
• W2912132559 hasAuthorship W2912132559A5021322016 @default.
• W2912132559 hasAuthorship W2912132559A5021929662 @default.
• W2912132559 hasAuthorship W2912132559A5022107546 @default.
• W2912132559 hasAuthorship W2912132559A5022480009 @default.
• W2912132559 hasAuthorship W2912132559A5024202047 @default.

• next